amgen has 'a lot to prove' in the weight-loss drug category, says mizuho's jared holz
Published 9 months ago • 3.2K plays • Length 5:05Download video MP4
Download video MP3
Similar videos
-
3:11
amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
-
4:31
blocking the horizon-amgen deal will be worse for pharma than for biotech, says mizuho's jared holz
-
5:47
zealand's obesity drug shouldn't disrupt novo nordisk-eli lilly leadership: mizuho's jared holz
-
6:41
chart of the day: amgen
-
1:50
cramer’s stop trading: amgen
-
1:16
amgen shares soar on obesity drug progress
-
5:09
dhea: the missing piece in the longevity puzzle? (my 5-month results)
-
8:26
a 3-year reflection. i regret freezing my eggs
-
1:04:53
anti-aging w/ rapamycin over 50: apoe4 carriers need to hear this! w/ alan green, md
-
5:46
amgen's weight loss drug:game-changer or missed opportunity? shares drop despite 20% results l amgen
-
2:07
amgen has great science, but they don't seem to make it across the finish line, says jim cramer
-
4:17
amgen stock prediction: amgen dives 5% despite 'truly remarkable' results for obesity treatment.
-
7:18
amgen cfo talks q2 earnings, obesity drug, and growth
-
3:25
what your amh levels can tell you？
-
1:16
cramer’s stop trading: amgen
-
1:18
get a closer look at amgen thousand oaks
-
6:49
amgen's obesity drug plans, outlook for 2024
-
3:50
amgen (amgn) sales higher after obesity drug results
-
3:33
jefferies' michael yee still likes amgen in the biotech sector
-
1:05
trio win nobel prize for oxygen research
-
2:08
who's a candidate for estrogen replacement therapy with san diego's james fontaine, md
-
0:15
next-level intelligence | enfagrow a mindpro